Search Results
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
MRD-driven addition of ibrutinib to venetoclax for CLL
CAPTIVATE: fixed-duration ibrutinib plus venetoclax in patients with CLL/SLL
AVO achieves high rates of undetectable MRD in CLL
Interim analysis of the FLAIR study: efficacy of ibrutinib plus venetoclax in IgHV unmutated CLL
5-year follow-up of patients with CLL treated in first-line with ibrutinib plus venetoclax
GLOW: Assessing ibrutinib plus venetoclax in CLL
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
Exploratory analysis of the CLARITY study: ibrutinib plus venetoclax in patients with R/R CLL
MRD outcomes from GLOW: venetoclax and ibrutinib in CLL
Ibrutinib plus venetoclax for first-line treatment of CLL: 4-year follow-up data
